Cegedim Czech Republic Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers. What has been the historical development of the Czech affiliate? Tomáš Nádvorník: Cegedim was established in the Czech Republic in…
Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…
Cegedim Romania To start off, we see that you have been with Cegedim Romania for 10 years, after running your own business initially. What would you say have been your main milestones and achievements since you have joined? Having been with a local and regional company at first, it has been quite…
Celgene UK and Ireland Celgene just announced very impressive second quarter results for its global operations, with a 38% increase in revenue partly led by strong growth in Europe. Within the global performance of the company, how would you assess the performance of the UK in 2010/2011? This year has been somewhat of a…
Association of Producers of generic medicines in Romania (APMGR) APMGR is obviously a rather young association that has only really been active since about a year now. Can you first comment on the timing that the Association was called into life? The timing has been quite good, as the generics industry is currently experiencing a strong momentum. Every country,…
National Agency for Medicines and Medical Devices (NAMMD) of Romania Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s pharmaceutical market. Over these five decades, thorough changes in the political regime, subsequent regulatory changes, the emergence of new institutions, and many other factors have drastically changed…
Genzyme Chile Genzyme was first established in Chile in 2004 but only opened its sales office in 2008, what was the rationale for the opening of the office at this time considering that you had been present in neighbouring countries 10 years before? The Chilean market is a very difficult one. We…
Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…
Pró Genéricos When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote it.” At that time, generics penetration was around 10.5% – now it’s around 20%. Does this reflect some fundamental change…
Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…
Cegedim Poland Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of Pharmaceutical Executive? On the one hand the pressures and incentives influencing the main stakeholders are the same as elsewhere. But…
See our Cookie Privacy Policy Here
